Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Injection Devices Evolving to Increase Capabilities


Injection Devices Evolving to Increase Capabilities and Market Share

Greystone Research Associates Examines New-Generation Syringes and Injectors and their Impact on the Injectable Drug Sector

(Amherst, NH) – The injectable drug sector has seen a marked increase in the level of device sophistication, patient-centered design, and drug/device integration, as specialty syringes and specialized injection devices proliferate in response to the safety and economic challenges posed by therapeutic injectables. Much of the activity in device evolution is being driven by the trend toward patient self-care as the administration of injectables moves increasingly from practitioner offices and healthcare facilities to patient homes.

As new drugs become available for the treatment of an expanding list of health conditions, drug developers have increasingly pursued packaging and delivery options that simplify the administration process and increase the efficiency and reliability with which the drug can be introduced into the patient. For injectable drugs, this pursuit has led to accelerated progress in injection device design, creating new opportunities and choices for drug marketers.

As injection device design evolves to address the needs of users and drug developers, a number of features have appeared that improve the drug administration experience. These enhancements include variable dose autoinjectors, dual chamber variable dose pen injectors, prefillable safety syringes, dose memory devices, tamper evident prefilled syringes, small form factor disposable autoinjectors, and prefilled needle-free injectors. On the horizon are more dramatic developments that include technology that will allow actuator-enabled needle-free injectors to be programmed to meet the needs of specific therapeutic drugs or patient profiles.

In terms of growth, prefilled syringes will continue to experience year-on-year unit growth of between 10 and 12 percent. We expect prefilled syringes to reach 4.75 billion units globally in 2016. Autoinjector growth will be slightly higher, as a growing list of therapeutic drugs supplied in prefilled syringes are bundled with autoinjectors and an increasing number of patients are introduced to autoinjectors as price points decline. The growth of pen injectors will decline slightly, as pressure from lower-cost feature-rich autoinjectors capable of accepting standard 1 mL prefilled syringes impacts pen demand in certain chronic disease segments. For needle-free injectors, prefilled devices will be the bright spot, as the success of Sumavel DosePro encourages other drug developers to consider this delivery device option, in particular for injectables indicated for pediatric patients.

A comprehensive analysis of advanced devices for injectables is included in a new and comprehensive report. The report – Advanced Devices for Injectable Drugs - includes assessments of devices, device features and injectable drug therapeutic markets, analysis of market factors, and profiles of market participants.

More information is available at
http://www.greystoneassociates.org

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Source: Greystone Research Associates

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Final Frontier: Rocket Lab And NASA Sign Commercial Space Launch Agreement

Rocket Lab has signed a Commercial Space Launch Act Agreement with the National Aeronautics and Space Administration (NASA). The agreement enables Rocket Lab to use NASA resources - including personnel, facilities and equipment - for launch and reentry efforts. More>>

ALSO:

Scoop Business: Wheeler Downplays Scope For ‘Large’ Rates Fall

Reserve Bank governor Graeme Wheeler says some market commentators are predicting further declines in interest rates that would only make sense for an economy in recession, although some easing is likely to be needed to maintain New Zealand’s economic growth. More>>

ALSO:

Ruataniwha Dam: Consent Conditions Could Mean Reduced Intensity

Legal advice sought by the Hawke’s Bay Regional Council on the Ruataniwha Dam consent conditions has confirmed that farmers who sign up to take water from the dam could be required to reduce the intensity of their farming operation to meet the catchment’s strict nitrogen limit. More>>

Health And Safety: Bill Now Sees Rules Relaxed For Small Businesses

Health and safety law reform sparked by the Pike River coalmine disaster has been reported back from the industrial relations select committee with weakened requirements on small businesses to appoint health and safety representatives and committees. More>>

ALSO:

Bearing Fruit: Annual Fruit Exports Hit $2 Billion For First Time

The value of fruit exported rose 20 percent (up $330 million) for the June 2015 year when compared with the year ended June 2014. Both higher prices and a greater quantity of exports (up 9.0 percent) contributed to the overall rise. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news